Therapy Areas: Inflammatory Diseases
Gannex Pharma's ASC42 receives FDA investigational new drug application approval
12 October 2020 -

Gannex Pharma Co Ltd, a subsidiary of China-based Ascletis Pharma Inc (HKEX: 1672), has received investigational new drug application approval from the United States Food and Drug Administration (FDA) for its drug candidate ASC42 in order to conduct clinical trials for non-alcoholic steatohepatitis (NASH) indication, it was reported on Sunday.

The company says that the product is an in-house developed, novel non-steroidal, selective, potent Farnesoid X Receptor agonist with best-in-class potential. In two NASH animal models, the product indicated significant improvements in liver steatosis, inflammation and fibrosis.

The product is an oral tablet formulation produced with proprietary therapy and is stable at room temperature.



Related Headlines